Clinical

Dataset Information

0

Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer


ABSTRACT: RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.Drugs used in chemotherapy, such as leucovorin, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy and bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase II trial is studying the side effects and how well giving cetuximab together with leucovorin, oxaliplatin, and fluorouracil works with or without bevacizumab in treating patients with resectable liver metastases from colorectal cancer.

DISEASE(S): Neoplasm Metastasis,Colorectal Cancer,Colorectal Neoplasms,Metastatic Cancer,Resectable Liver Metastases Of Colorectal Cancer

PROVIDER: 2037375 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2047382 | ecrin-mdr-crc
2022-01-21 | GSE154524 | GEO
| 2045339 | ecrin-mdr-crc
| 2010414 | ecrin-mdr-crc
| 2012075 | ecrin-mdr-crc
| 2101117 | ecrin-mdr-crc
| 2046482 | ecrin-mdr-crc
| 2026285 | ecrin-mdr-crc
| 2024429 | ecrin-mdr-crc
| 2046289 | ecrin-mdr-crc